New publication in MCP: Improving MHC ligand identification with machine learning and optimized isolation

Blog cover for Ardigen publication on ARDisplay-I and MHC ligand identification in Molecular & Cellular Proteomics

Identification of MHC ligands through allele-guided isolation combined with machine learning for improved MHC assignment using ARDisplay-I

We’re pleased to share a new publication in Molecular & Cellular Proteomics (MCP) co-authored by Ardigen researchers, focused on improving MHC ligand identification and accurate assignment, an important step in T cell–based immunotherapies.

By combining optimized experimental approaches with machine learning, the study provides a more accurate way to interpret peptides displayed on the cell surfac

What’s the study about?

MHC ligand identification is essential for discovering targets for immunotherapies, but it remains challenging – particularly when peptides are found at low abundance on the cell surface.

In this study, the team:

  • showed how isolation strategy and separation conditions directly influence which MHC ligands are recovered, down to individual epitopes
  • demonstrated that peptide detection depends on properties such as hydrophobicity, post-translational modifications, and the presenting HLA allele
  • developed ARDisplay-I, a machine learning model that improves assignment of peptides to specific MHC alleles

ARDisplay-I was benchmarked against established tools such as netMHCpan, MixMHCpred, and MHCflurr and outperformed them in predicting MHC class I ligand presentation.

Study significance

Selecting the right targets is one of the most critical steps in T cell–based immunotherapies – and it depends directly on how well MHC-bound peptides can be captured and interpreted.

Both experimental design and computational modeling play a role here. Combining optimized isolation strategies with machine learning improves both the visibility of relevant peptides and confidence in identifying which MHC alleles present them, especially in complex, multiallelic samples.

Together, these advances support a more reliable transition from experimental data to actionable therapeutic targets.

Authors

We would like to congratulate all co-authors on this achievement and thank everyone involved for their valuable contributions:

Shima Mecklenbräuker, Piotr Skoczylas, Paweł Biernat, Badeel K.H.Q. Zaghla, Bilge Atay, Mai Hossam, Bartłomiej Król-Józaga, Maciej Jasiński, Victor Murcia Pienkowski, Anna Sanecka-Duin, Oliver Popp, Mohamed Haji, Rafał Szatanek, Philipp Mertins, Jan Kaczmarczyk, Ulrich Keller, Agnieszka Blum, Martin G. Klatt.

You might be also interested in:

Poster: Bridging the Phenotype-Proteome Gap: A Multi-Modal AI Framework for analysis of Cell Painting images
Biomedical knowledge graph connecting drug discovery data, disease biology, targets and indications to support target prioritization and indication expansion
Knowledge Graphs in Drug Discovery: Bringing Context to Internal Data Assets
Molecular structure representing AI-supported antibody design for blood-brain barrier research
How BBB-Penetrating Antibodies Cross the Blood-Brain Barrier
Life sciences conference takeaways 2026 - AACR, PEGS Boston, SLAS Europe, and Bio-IT World summary on AI in drug discovery
What 4 Life Sciences Conferences Revealed About AI in Drug Discovery

Contact

Ready to transform drug discovery?

Discover how one of the top AI CROs in the world, can be your trusted partner in revolutionizing drug discovery through AI.

Contact us today to learn more about our tailored solutions for empowering your drug development journey.

Send us a message and we will contact you back within 48 hours.

Newsletter

Become an insider

Be the first to know about Ardigen’s latest news and get access to our publications, webinars and more!